Form 8-K OCULAR THERAPEUTIX, INC For: Aug 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/6/2026
- S&P 500, Nasdaq close sharply higher as Broadcom rallies
- Oil prices settle at pre-Iran war levels as crude output grows
- Broadcom stock pops 4% as Apple silicon deal gets extended through 2031
- Buy the pullback in chip stocks, JPM's Matejka says
- Memory stocks rebound as analysts flag a buying opportunity
- Rivian Automotive (RIVN) files for 75M share offering
- Nokia OYJ (NOKIA:FH) (NOK) PT Raised to EUR14 at Kepler Cheuvreux
- Rivian offers Q2 2026 revenue outlook, cash position grows
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Broadcom secures role as key Apple supplier with chip deal through 2031
Clear Street Reiterates Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:11 AM EDTClear Street analyst Bill Maughan reiterated a Buy rating and $18.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "OCUL is trading down (-6%, XBI +/- 0%) after reporting 2Q25 earnings. Revenue was roughly in line ($13.5M vs $13.6M) and expenses outpaced expectations ($51.1M vs $43.1M). But we believe the weakness today is caused by the disclosure that the company tapped into its ATM for $97M in... More
Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL)
August 5, 2025 11:07 AM EDTRaymond James analyst Dane Leone reiterated a Strong Buy rating and $19.00 price target on Ocular Therapeutix (NASDAQ: OCUL).
The analyst comments "Tuesday, before market open, Ocular Therapeutix reported 2Q25 financial results. Management hosted a call to discuss recent progress and outlook for the remainder of 2025. The company reported $13.5M in total revenue vs. our estimated $12.0M and diluted EPS of $(0.39) vs. our... More
